1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80

BACKGROUND: Lenacapavir (LEN) is a highly potent, long-acting, first-in-class inhibitor of HIV-1 capsid protein approved for the treatment of HIV-1 infection in adults with multidrug resistance in combination with other antiretrovirals. CALIBRATE is an ongoing phase 2 study in people with HIV-1 (PWH...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Princy N, Goldstein, Deborah A, Hengel, Richard L, Gaur, Aditya H, Wurapa, Anson K, Khalsa, Ann M, Newman, Cheryl L, Saunders, Gary, Liu, Shan-Yu, Dvory-Sobol, Hadas, Rhee, Martin, Gupta, Samir K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677782/
http://dx.doi.org/10.1093/ofid/ofad500.1416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677782/
http://dx.doi.org/10.1093/ofid/ofad500.1416

Ejemplares similares